GILD Gilead Sciences Inc BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) Best Biotech Stocks 2026 →

Gilead Sciences (GILD) Stock: Buy, Sell, or Hold?

$168.08
+0.13 (+0.08%) ▲
5d: +0.71% 30d: +6.81% 90d: +20.99%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (41%)
Quality Score
47/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$150.50 – $168.28
Position: SLIGHTLY HIGH
Forward P/E & Valuation
16.6x FAIR
vs 14.5x historical avg
Wall Street Target
$174.77
+4.0% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$164.00 / $176.58
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
ℹī¸ NEUTRAL: GILD is fairly priced but lacks strong directional signals. At 4.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Nov 4, 2026 at $173.04 · last confirmed Nov 13, 2026

Strength: 5.0/10

Get Alerted When GILD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$205.78
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$127.77
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: GILD is currently trading at $168.08, which is considered slightly high relative to its 30-day fair value range of $150.50 to $168.28. From a valuation perspective, the stock is trading at a premium (Forward PE: 16.6) compared to its historical average (14.5). At these levels, the market is pricing in 4.5% annual earnings growth.

Technical Outlook: Technically, GILD is in a strong uptrend. The price is currently testing key support at $164.00. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: GILD scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $150.50 - $168.28
Company Quality Score 47/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 41.4%

Trading Range & Key Levels

30-Day Trading Range $150.50 - $168.28
Current vs Trading Range SLIGHTLY HIGH
Support Level $164.00
Resistance Level $176.58
Current Trend Strong Uptrend
Technical data as of Nov 13, 2026

Protect Your Profits

Holding GILD? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Quantitative Signal Breakdown

  • BEARISH: Weak technical setup (30/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($174.77)
  • BULLISH: Expecting earnings turnaround to 4.5% growth with 6.8% revenue growth
  • WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 16.59
Wall Street Target $174.77 (+4.0%)
Revenue Growth (YoY) 6.8%
Earnings Growth (YoY) -20.2%
Profit Margin -12.5%
Valuation Premium vs History +4.5% premium
PE vs Historical 16.6 vs 14.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +4.5% (market-implied from PE analysis)
1-Year Target $175.64 (+5%)
2-Year Target $183.55 (+9%)
3-Year Target $191.81 (+14%)
3-Yr Target (if PE normalizes) (PE: 17→15) PE COMPRESSION $167.59 (0%)
Earnings growth offset by PE compression
Share GILD Analysis

Share this live GILD analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

Reddit StockTwits X / Twitter
bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (GILD)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary: Gilead Sciences' HIV business, led by Biktarvy and Descovy, continues to drive growth with strong sales and market share. Twice-yearly injectable Yeztugo is a key growth driver due to its adherence advantages and broad patient population.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 5:46 AM ET
Data refreshes hourly during market hours. Next update: 6:46 AM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
See Full Scanner Results »
Technical Signals Check

Is GILD showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for GILD.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
LLY
Eli Lilly and Company 		STRONG BUY
31 analysts 		$1453 39 SELL
ABBV
AbbVie Inc 		STRONG BUY
29 analysts 		$306 49 HOLD
MRK
Merck & Company Inc 		BUY
28 analysts 		$162 53 HOLD
BIIB
Biogen Inc 		BUY
36 analysts 		$266 41 HOLD
JNJ
Johnson & Johnson 		BUY
23 analysts 		$279 53 HOLD
LLY Eli Lilly and Comâ€Ļ
39 SELL
ABBV AbbVie Inc
49 HOLD
MRK Merck & Company Iâ€Ļ
53 HOLD
BIIB Biogen Inc
41 HOLD
JNJ Johnson & Johnson
53 HOLD

Advanced GILD Option Strategies

Professional options setups generated by AI based on today's GILD price and gamma walls.

Iron Condor Bull Call Bear Put Collar

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive GILD Research Pages
GILD Technical Chart GILD Price Prediction GILD Intrinsic Value DCF GILD Earnings Date GILD Investment Advisor GILD Fair Price Analyzer GILD Options Chain GILD Options Advisor GILD Options Analysis GILD Competitors
Part B: Tradestie Flagship Market Scanners
Today's Best Signals (GILD) Sector Rotation Monitor AI Supply Chain Money Flow Gamma Squeeze (GEX) Scanner Undervalued Stocks Scanner Insider Cluster Buying Reddit & WSB Sentiment Tracker Backtested Stock Scanner
Compare GILD with Peers
GILD vs AMGN
Which one to buy?
GILD vs BIIB
Which one to buy?
GILD vs ABBV
Which one to buy?
GILD vs BMY
Which one to buy?
GILD vs REGN
Which one to buy?
CDTX vs GILD
ADP vs GILD
GILD vs MSTR
GILD vs PAYX
DLTR vs GILD
GILD vs TECH
GILD vs MRNA
GILD vs IOVA
CGTX vs GILD
BIIB vs GILD
Create New Comparison View All Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals